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Background: The process of obtaining informed consent continues to be a contentious issue in clinical and public
health research carried out in resource-limited settings. We sought to evaluate this process among human research
participants in randomly selected active research studies approved by the School of Medicine Research and Ethics
Committee at the College of Health Sciences, Makerere University.
Methods: Data were collected using semi-structured interviewer-administered questionnaires on clinic days after
initial or repeat informed consent procedures for the respective clinical studies had been administered to each
study participant.
Results: Of the 600 participants interviewed, two thirds (64.2%, 385/600) were female. Overall mean age of study
participants was 37.6 (SD = 7.7) years. Amongst all participants, less than a tenth (5.9%, 35/598) reported that they
were not given enough information before making a decision to participate. A similar proportion (5.7%, 34/597)
reported that they had not signed a consent form prior to making a decision to participate in the study. A third
(33.7%, 201/596) of the participants were not aware that they could, at any time, voluntarily withdraw participation
from these studies. Participants in clinical trials were 50% less likely than those in observational studies [clinical trial
vs. observational; (odds ratio, OR = 0.5; 95% CI: 0.35-0.78)] to perceive that refusal to participate in the parent
research project would affect their regular medical care.
Conclusions: Most of the participants signed informed consent forms and a vast majority felt that they received
enough information before deciding to participate. On the contrary, several were not aware that they could
voluntarily withdraw their participation. Participants in observational studies were more likely than those in clinical
trials to perceive that refusal to participate in the parent study would affect their regular medical care.Background
With the growing volume of clinical and public health re-
search in developing countries, increasing attention is
now focused on how existing research regulatory mechan-
isms are performing in protecting study participants [1].
In these countries, study participants’ socioeconomic sta-
tus, education level as well as health conditions have been
found to render them vulnerable [2–4] to exploitation [5].
To protect such participants, it necessitates establish-
ment of functioning independent ethics review commit-
tees to evaluate the research protocols before recruitment
commences [6]. These committees present the first and a
principal step for independent review of the scientific
and ethical quality of research proposals before their* Correspondence: kiguba@googlemail.com
Makerere University College of Health Sciences, Kampala, Uganda
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reproduction in any medium, provided the orimplementation. That notwithstanding, informed con-
sent continues to be a contentious issue in clinical and
public health research carried out in resource-limited
settings [7].
The assumption that the approved research protocol is
predictive of the actual implementation process may not
necessarily be true thus requiring ethics committees to
exercise their responsibility of monitoring the conduct
of ongoing research projects and the consent process
[8]. However, human and non-human resource constraints
coupled with an increase in the volume of research pro-
jects conducted may present logistical challenges in the
execution of this function [7, 9–12]. Whereas available
guidelines prescribe specific ethical standards for the
informed consent process [13–17] circumstances may arise
in which these standards are not explicit [7] resulting inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of study participants
Sociodemographic characteristics
Age, mean (SD), yr 37.6 (7.7)
No formal education (n, %) 53 (8.9)
Female Gender (n, %) 385 (64.2)
Informed Consent Process No
First research project for participant 8.0 % (48/600)
Felt were given enough information* 5.9 % (35/598)
Signed a consent form* 5.7 % (34/592)
Felt pressured to participate* 95.0 % (568/598)
Refusal to participate would affect
regular medical care*
59.8 % (357/597)
Anticipated benefits for participation* 7.0 % (42/599)
Anticipated risks for participation 68.2 % (409/600)
Knowledge of voluntary withdrawal* 33.7 % (201/596)
*The numbers do not add up to 600 participants due to missing data.
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search project implementation.
Without routine monitoring of research activities, the
ambiguity of ethical standards in the consenting process
may create room for compromise and laxity among re-
search project implementers resulting in violation of the
rights and welfare of research participants [18].
To our knowledge, a few studies have explored the
quality of informed consent in resource-limited settings
[3, 19–23]. However, there is a paucity of published litera-
ture on this subject in the Ugandan setting. This study
aimed to evaluate the informed consent process among
human research participants in randomly selected active
research projects approved by the School of Medicine Re-
search and Ethics Committee at the College of Health
Sciences, Makerere University, Kampala, Uganda.
Methods
We conducted a cross-sectional study over a period of
one month from 28th July 2008 to 22nd August 2008.
Ethical approval for this study was granted by the School
of Medicine Research and Ethics Committee (SOMREC),
Makerere University College of Health Sciences.
Study sample
Study participants involved in the consent evaluation
process were drawn from clinical trials and observational
studies that had received ethical clearance from the
SOMREC. All selected studies were conducted at the
Mulago National Referral Hospital, and the Infectious
Diseases Institute, both of which are located adjacent to
the Makerere University College of Health Sciences.
Eight clinical trials and seven observational studies were
selected. All selected clinical trials were treatment trials
among HIV-infected patients. Treatments tested included
antiretroviral therapy, Herpes Simplex Virus type 2 (HSV-2)
suppression, antibiotics, antimalarials, and computerized
cognitive rehabilitation training. All selected observa-
tional studies (except one specific to Tuberculosis) were
also focused on HIV-infected patients. These included
observations of renal features in HIV-infected patients,
studies of CD4 trends, immune reconstitution inflam-
matory syndrome after commencing antiretroviral ther-
apy, and HIV-1 co-receptor tropisms.
The format of informed consent forms for all selected
studies adhered to the guidelines recommended by the
SOMREC which, at the minimum, stipulate inclusion of
sections on purpose of the research, study procedures,
discomforts and risks, potential benefits, privacy and
confidentiality, compensation for participation, voluntary
participation, investigators’ contact information for ques-
tions about study, and ethics committee contact for
questions about rights and welfare of participants. Read-
ability levels of the English versions of consent formswere set at primary school level (grade level 6) and trans-
lated into the mainly spoken local language “Luganda” for
participants who preferred the local language and those
who did not have any formal education. Informed consent
was obtained from each participant prior to recruitment
into our study. The required sample size of 600 partici-
pants was obtained by consecutively sampling study parti-
cipants from each of the selected active clinical studies.
Data collection methods
Data were collected by five research assistants on re-
search clinic days after initial or repeat informed consent
procedures for the respective clinical studies had been
administered to each study participant. We used semi-
structured interviewer-administered questionnaires to
collect the data. The research assistants were supervised
throughout the process of data collection.
Data management and analysis
Quantitative data were entered into EpiData version 3.1
and exported to SPSS 12.0 for statistical analysis. The
results are presented as simple proportions, means, fre-
quencies, bar charts, and odds ratios with their 95%




The overall mean age of respondents was 37.6 (SD = 7.7)
years and about two-thirds (64.2%, 385/600) of them were
female (Table 1). The mean age of respondents enrolled in
clinical trials (38.2, SD = 7.5) was statistically significantly
higher than that of respondents in observational studies
(36.7, SD = 7.3) (Table 2). Whereas just under a tenth
Table 2 Characteristics of study participants stratified by clinical trial vs. observational study
Sociodemographic characteristics
Clinical Trial± Observational± P-value
Mean age (mean, SD), yr 38.2 (7.5) 36.7 (7.3) 0.027
No formal education (n, %) 39 (16.6) 81 (30.7) 0.001
Female Gender (n, %) 146 (62.1) 173 (65.8) NS
Informed Consent Process No aOR
First research project for participant* 5.1 % (12/235) 8.3 % (22/264) NS
Felt were given enough information* 3.0 % (7/235) 7.3 % (19/262) 0.3(0.13-0.84)
Signed a consent form* 4.3 % (10/234) 6.6 % (17/258) NS
Felt pressured to participate* 99.1 % (232/234) 95.1 % (251/264) NS
Refusal to participate would affect regular medical care* 48.5 % (113/233) 65.4 % (172/263) 0.5(0.35-0.78)
Anticipated benefits for participation* 1.7 % (4/235) 2.7 % (7/263) NS
Anticipated risks for participation* 68.9 % (162/235) 65.9 % (174/264) NS
Knowledge of voluntary withdrawal* 28.8 % (67/235) 36.4 % (96/264) NS
*The overall numbers in rows do not add up to 600 participants due to missing data.
± Data on clinical trial vs. observational study status were available for 499 out of 600 participants with 235 in clinical trials and 264 in observational studies.
aOR Odds Ratio adjusted for age, gender, educational level and whether participant was involved in an initial or repeat consent process.
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mal education, more than a half (52.4%, 313/597) had, at
least, attained secondary level education (Figure 1). How-
ever, respondents in observational studies were almost
twice as likely to have no formal education as compared to
those in clinical trials and this difference was significant (P =
0.001) (Table 2). Ten per cent (10%, 60/598) of participants
were initial consenters while the rest (90%, 538/598)
were repeat consenters. In this survey, 5.9% (35/598) of
participants reported that they were not given enough
information prior to making a decision to participate in
the study.
On a visual analogue scale (0 to 10 arbitrary scores, 0 =
not satisfied at all, 10 = fully satisfied), close to half
(45.4%, 271/597) recorded a score of 10 indicating thatFigure 1 Highest Level of Education attained among 597 participantsthey were fully satisfied with the informed consent
process. The mean satisfaction score was 8.73 (SD = 1.57)
and the data were normally distributed. There was no sta-
tistically significant difference between mean scores of ini-
tial versus repeat consenters. Amongst the reasons reported
for not signing consent forms, participants (73.5%, 25/34)
reported that they were not given a form to sign (72%,
18/25), received the form but did not want to sign
(20%, 5/25), and did not know the reason (8%, 2/25).
Of 598 (99.7%) out of 600 respondents, 568 (95%) indi-
cated that they felt no pressure to participate in the
parent study, 28 (4.7%) felt pressured to participate,
while 2 (0.3%) were not sure. Amongst individuals who
signed a consent form, a comparable proportion (4.5%)
of subjects felt pressured to participate in the parent.
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sign a consent form reported that they felt pressured to
enroll in study, 5.9% (2/34) were not sure if they were
pressured or not.
Overall, the majority (93%, 557/599) of respondents
believed that there were personal benefits for participat-
ing in the study. Thirty (5%) individuals were not sure
whether they would receive benefits for participation in
the study while 12 (2%) did not expect any benefits.
Ninety six per cent (96.2%, 226/235) of participants in
clinical trials and 91.3% (240/263) of those in observa-
tional studies expected benefits but these proportions
were not significantly different (P = 0.07). Amongst
those who expected benefits, the most frequently cited
benefits were direct (81.7%) while the others cited were
indirect (18%). Direct benefits mentioned related to
medical gains derived from administered interventions
while indirect benefits related to greater access to profes-
sional health care. A little more than two-thirds (68.2%,
409/600) of respondents believed that there were no risks
for participation in the study. The most frequently
reported risks were physical (60.2%) followed by psycho-
logical (23.1%), economic (11.1%), and social harm (5.6%).
A third (33.7%, 201/596) of the participants were not
aware that they could, at any time, voluntarily withdraw
participation from these studies.
Respondents in clinical trials were 50% less likely to
perceive that refusal to participate in the study would
affect their regular medical care [clinical trial vs. obser-
vational; (OR = 0.5; 95% CI: 0.35-0.78)] (Table 2).
Discussion
This research study elicited information on the adequacy
of the application of the basic elements in obtaining
informed consent in a range of research studies con-
ducted among participants in our setting. The majority
of participants reported that they were given enough in-
formation to participate in the research studies and similar
results have been obtained elsewhere [2]. This finding was
corroborated with the very high overall informed consent
process satisfaction scores. In addition, the largest propor-
tion of participants did not feel pressured to participate in
the research studies.
Sanchez et al. [20] observed that before taking part in
a clinical trial, participants assessed perceived benefits
and risks, their rights and responsibilities as well as their
understanding of what research and volunteering meant.
Processing this information before deciding to enroll
enhanced commitment to the study and promoted parti-
cipants’ right to choose without coercion [20]. One study
in the developed world however, indicated that the infor-
mation participants received did not have to be ‘very
good’ or even ‘good’ to be perceived as adequate [24].
Moreover many of those who reported that they hadreceived adequate information did not know or even re-
member about the liberty to withdraw [24]. Conversely,
participants in developing country settings may fail to
appropriately process this information thus affecting free
choice due to low awareness of their rights, their scarce
questioning of risks involved [20], power relations be-
tween them and the researcher [19], and failure to
understand that participation has a research purpose
apart from whatever benefits that might arise [2, 25].
Participants in observational studies, however, were
more likely to report that they were not given enough
information before making a decision to participate
when compared to those in clinical trials. This may be
interpreted to suggest that investigators probably go an
extra mile to provide information during the rigorous
process of recruiting participants for clinical trials.
Investigators are compelled to do more due to the strin-
gent regulatory framework, the complex nature, and risk
attributed to clinical trials. This may also partly explain
why participants in clinical trials were less likely than
those in observational studies to perceive that refusal to
participate in the study would affect their regular med-
ical care.
Overall, almost all (including all initial consent) parti-
cipants believed that there were benefits for participating
in the clinical study but only about one third believed
that there were risks. This observation, which may sug-
gest therapeutic misconception, has been described else-
where [26, 27] and is consistent with other studies in a
developing country setting where participants antici-
pated improved clinical care and downplayed the risks
associated with clinical research [28].
Amongst those who expected benefits, the most fre-
quently cited benefits were direct while a few cited were
indirect. Direct benefits mentioned related to medical
gains derived from administered interventions while in-
direct benefits related to greater access to professional
health care. In randomised clinical trials, it is important
to explain to research participants that they have an
equal chance of being assigned to either the intervention
arm or to the comparison arm and that at the onset of a
well designed randomized clinical trial, it is not known
which arm will provide direct benefit. However, whether
or not participants receive the experimental interven-
tion, they may receive indirect benefits in the form of
more attention from health worker, closer follow-up,
and screening tests or additional tests to determine out-
comes. These collateral benefits might lead to improved
clinical outcomes even in situations where the interven-
tion is no better than standard of care[29, 30]. In some
observational study designs, especially surveys and
reviews of existing medical records, there are no direct
benefits but research participants may receive indirect
benefits as is the case with clinical trials.
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were not aware that they could voluntarily withdraw
their participation at any time despite the fact that all
the studies selected had incorporated this section in
their consent forms. Conversely, a study on comprehen-
sion of informed consent in rural and peri-urban Mali
observed that 90% of respondents did not understand
withdrawal criterion [25]. This finding is not limited to
developing countries since similar experiences have been
reported in the developed world [24]. Lynoe et al.
observed that deficiencies in participants' perception of
information during the consent process may be caused
by informers rather than the participants [24]. This may
partly explain why participants in clinical trials who are
usually taken through more rigorous consent processes
by informers are less likely than those in observational
studies to perceive that refusal to participate may affect
their regular medical care. However, participants in ob-
servational studies were almost twice as likely to have no
formal education as compared to those in clinical trials
and this may also explain their higher likelihood to per-
ceive that they would be denied regular medical care if
they turned down an invitation to take part in the re-
search studies. This finding is consistent with results
obtained elsewhere which observed that level of educa-
tion is a key factor in determining the outcome of the
informed consent process[3, 4].
One in every 20 participants did not sign a consent
form. The majority of them reported that they were not
given the consent form to sign. This is a violation of
Good Clinical Practice (GCP) standards which stipulate
that, whenever consent is not waived, every research
participant or the research participant’s representative
must sign and date the consent document [31]. If the
participant is illiterate, a thumbprint should be used in-
stead [31]. This underlines the need for ethics commit-
tees to conduct study site visits as they execute their
role of research oversight, although more capacity build-
ing will be required for ethics committees in resource-
limited settings [10–12] to fully exercise this mandate.
Relevant empirical data is required to inform the over-
all policy efforts focused towards protecting the rights
and welfare of study participants in resource-limited set-
tings and our study aimed to contribute towards this
cause.
This study has several important limitations. First, we
did not investigate in-depth the recall and comprehen-
sion aspects of informed consent in the selected clinical
studies. This would have facilitated a better assessment
of risk factors for poor consenting processes in our set-
ting. Second, we used self-report for all our measure-
ments which may have yielded socially desirable answers
from participants. Third, the median duration of partici-
pants in the research studies was 2 years. Such participantsmay have undergone several sessions of informed consent
and may not be representative of the responses that would
have been obtained from first-time participants recently
enrolled in clinical studies. Stratified analyses attempted to
identify differences between initial and repeat consent par-
ticipants and the two groups appeared to differ only if par-
ticipants were enrolled into their first ever parent study.
Conclusions
Most of the participants signed informed consent forms
and the majority felt that they had received enough infor-
mation before deciding to participate in the parent studies.
On the contrary, not all were aware that they could volun-
tarily withdraw their participation. Participants in observa-
tional studies were more likely than those in clinical trials
to perceive that refusal to participate in the parent study
would affect their regular medical care.
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